Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.34 |
| ▸ | CA7 | P43166 | 1/20 | 0.34 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.34 |
| ▸ | INPP5A | Q14642 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | DRD2 | P14416 | 8/20 | 0.32 |
| ▸ | HTR2A | P28223 | 8/20 | 0.32 |
| ▸ | DRD3 | P35462 | 8/20 | 0.32 |
| ▸ | G6PD | P11413 | 3/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23119128 | 0.89 | CA1 (0.33) | CA12CA7CA14G6PD | |
| SCHEMBL17723319 | 0.89 | CA1 (0.33) | CA12CA7CA14G6PD | |
| SCHEMBL17723335 | 0.89 | CA1 (0.33) | CA12CA7CA14G6PD | |
| SCHEMBL8201280 | 0.88 | CA12 (0.42) | CA12CA7CA14HTTDRD2 | |
| SCHEMBL15014471 | 0.88 | CA12 (0.42) | CA12CA7CA14HTTDRD2 | |
| SCHEMBL8294594 | 0.88 | CA12 (0.42) | CA12CA7CA14HTTDRD2 | |
| SCHEMBL24659043 | 0.85 | KAT8 (0.32) | — | |
| SCHEMBL25011506 | 0.85 | KAT8 (0.32) | — | |
| SCHEMBL12555215 | 0.81 | JAK2 (0.36) | CA12CA7CA14INPP5AHTT | |
| SCHEMBL17778085 | 0.76 | KCNH2 (0.35) | CA12CA7CA14G6PD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2011-08-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110201593-A1 | TRICYCLIC HETEROCYCLIC COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | CCNY, CCNA1, CCNA2 | CA12 2341/4885CA7 1763/4885CA14 2378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.